Venot, Quitterie
Blanc, Thomas
Rabia, Smail Hadj
Berteloot, Laureline
Ladraa, Sophia
Duong, Jean-Paul
Blanc, Estelle
Johnson, Simon C.
Hoguin, Clément
Boccara, Olivia
Sarnacki, Sabine
Boddaert, Nathalie
Pannier, Stephanie
Martinez, Frank
Magassa, Sato
Yamaguchi, Junna
Knebelmann, Bertrand
Merville, Pierre
Grenier, Nicolas
Joly, Dominique
Cormier-Daire, Valérie
Michot, Caroline
Bole-Feysot, Christine
Picard, Arnaud
Soupre, Véronique
Lyonnet, Stanislas
Sadoine, Jeremy
Slimani, Lotfi
Chaussain, Catherine
Laroche-Raynaud, Cécile
Guibaud, Laurent
Broissand, Christine
Amiel, Jeanne
Legendre, Christophe
Terzi, Fabiola
Canaud, Guillaume
Article History
Received: 1 March 2017
Accepted: 16 May 2018
First Online: 13 June 2018
Change Date: 3 April 2019
Change Type: Correction
Change Details: The ‘Competing interests’ statement of this Article has been updated; see accompanying Amendment for further details.
Competing interests
: A patent application (WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Descartes, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES syndrome). G.C. is the inventor.